Apellis Pharmaceuticals (NASDAQ:APLS) had its price target hoisted by research analysts at JPMorgan Chase & Co. from $31.00 to $35.00 in a report issued on Friday. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 42.86% from the stock’s current price.
A number of other research analysts have also recently commented on APLS. B. Riley began coverage on Apellis Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $27.00 target price on the stock. Evercore ISI began coverage on Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued an “outperform” rating on the stock. Finally, Citigroup began coverage on Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued a “buy” rating and a $23.00 target price on the stock.
Apellis Pharmaceuticals (NASDAQ APLS) opened at $24.50 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 27.79 and a quick ratio of 2.75. Apellis Pharmaceuticals has a 12 month low of $12.45 and a 12 month high of $27.53.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3298375/apellis-pharmaceuticals-apls-pt-raised-to-35-00-at-jpmorgan-chase-co.html.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.